Pam Mangat-Dhaliwal: How ASCO is putting its commitment to patient advocacy into action
Pam Mangat-Dhaliwal, Division Director of Clinical Research and Analytics at ASCO, shared a post on LinkedIn:
“American Society of Clinical Oncology (ASCO)’s CDK Study investigating optimal dosing strategies for patients with metastatic breast cancer, serves as a powerful example of how ASCO is putting its commitment to patient advocacy into action.
The CDK Study incorporates patient perspectives into every stage of clinical trials, from design to dissemination of results.
Learn more from ASCO’s latest ASCO Connection.”
More posts featuring Pam Mangat-Dhaliwal.
Pam Mangat-Dhaliwal is the Division Director of Clinical Research and Analytics at the American Society of Clinical Oncology (ASCO). She leads ASCO’s first clinical trial, the Targeted Agent and Profiling Utilization Registry (TAPUR) Study, which is a national precision medicine phase II non-randomized basket trial.
Additionally, she collaborates on various research projects with both internal and external partners. Mangat-Dhaliwal is also a member of the Program Committee for the Society for Clinical Trials and possesses expertise in pragmatic trials, clinical trial diversity, research methodologies, data management, oncology, and biomarkers.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023